Effects of a Progestin, Quingestanol, in Older Diabetic Women

Abstract

Quingestanol acetate (17-α-ethynyl-19-nortestosterone acetate, 3-cyclopentylenol ether), a synthetic progestational steroid, was well tolerated at a dosage of 300 µg/day per os by 17 diabetic women who, with but one exception, were between 50 and 65 years of age and had ceased menstruating. Body weight, systolic and diastolic blood pressure, and the pulse rate were of the same orders of magnitude prior to and during the 12 months of quingestanol treatment. The diabetes mellitus was not affected but oscillometric readings at certain body points decreased during the year of treatment, probably reflecting the natural course of vascular disease in diabetic individuals.Despite changes in certain laboratory indices, i.e. slight increases of variable but usually short duration in serum sodium, chloride, total globulins and their α₂, β- and γ-fractions, SGOT, SGPT, LDH, FSH, chylomicrons, and blood platelets and the decreases in serum potassium, albumin, α₁-globulin, nonesterified fatty acids, β-lipoproteins, and plasma ll(OH)corticosteroids, most of the values remained within the ranges established for normal persons. One year of quingestanol therapy was associated with decreased first-day responses to metyrapone. This suggests, among other possibilities, that quingestanol inhibits the hypothalamic-pituitary controlled output of ACTH.All of the other items monitored during this course of quingestanol therapy remained unchanged.

Ether derivatives of a progestin and estrogen in monthly dosage

“…t33.2 ± 15.3 (10) t3.4 ± 3.0 (10) t 18.6 ± 11.9 (10) t6.2 ± 6.3 (10) "9.7 ± 0.4 (11) "9.3 ± 0.3 (11) t3.7 ± 0.4 (11) *2.9 ± 0.4 (11) 112 ± 44 (10) 142 ± 53 (10) "315 ± 47 ( 7) "411 ± 93 ( 7) 12 months X ± SD (n) "2l.7 ± 13.1 (11) "33.7 ± 5.3 (11) fl4.8 ± 7.9 ( 8) t30.8 ± 7.9 ( 8) "7.9 ± 5.8 (11) "18.0 ± 14.8 (11) 52.3 ± 20.7 (11) 66.5 ± 16.6 (11) 459 mg Cortrosyn in 2 minutes with measurement af plasma 11 (OH) corticosteroids at 3 hours. ception of vibrations assessed by Bio-Thesiometer 2 ) , and oscillometric readings did not indicate any consistent trends.…”

“…In prior reports7, 10 we have described changes in endocrine and other indices during treatment with synthetic steroids that possess an ether grouping, marked solubility in body fat, and prolonged duration of action, i.e., quingestanol acetate, a progestational agent, and quinestrol, an estrogenic analog ( Fig. 1).…”

“…t33.2 ± 15.3 (10) t3.4 ± 3.0 (10) t 18.6 ± 11.9 (10) t6.2 ± 6.3 (10) "9.7 ± 0.4 (11) "9.3 ± 0.3 (11) t3.7 ± 0.4 (11) *2.9 ± 0.4 (11) 112 ± 44 (10) 142 ± 53 (10) "315 ± 47 ( 7) "411 ± 93 ( 7) 12 months X ± SD (n) "2l.7 ± 13.1 (11) "33.7 ± 5.3 (11) fl4.8 ± 7.9 ( 8) t30.8 ± 7.9 ( 8) "7.9 ± 5.8 (11) "18.0 ± 14.8 (11) 52.3 ± 20.7 (11) 66.5 ± 16.6 (11) Hematology. The relative blood cell volurne or hematocrit, hemoglobin, erythrocyte, total and polymorphonuclear leukocyte, and sedimentation rate 34 data remained constant in sampies of shed peripheral blood.…”